venBio Global Strategic Fund IV, L.P. bought $6.5M of Attovia Therapeutics (ATTO)

Executed Aug 6, disclosed Aug 10, 4 days later.

Value, as filed

$6.5M

382,352 sh × $17.00

Executed

Aug 6

the trade date, as filed

Disclosed

Aug 10

4 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

+17.3%

+9.8% from execution

Over the 21 trading sessions from the disclosed entry session (Aug 10), the stock returned +17.3% (delay-adjusted); from the execution session (Aug 6), +9.8%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

VP venBio Global Strategic Fund IV, L.P. 10% owner profile →

venBio Global Strategic Fund IV, L.P. (10% owner) filed 1 Form 4 report as a reporting entity in the trailing twelve months (1 purchase, 0 sales), most often in Attovia Therapeutics, Inc. Common Stock (ATTO). Across 1 priced purchase filing, the average 21-session return was +9.8% from execution and +17.3% from disclosure (delay-adjusted; derived). The largest single filing was $6.5M of ATTO (382,352 sh × $17.00, as filed), executed Aug 6.

The name

ATTO

Attovia Therapeutics, Inc. Common Stock ATTO · 8 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→